Late molecular relapse in two CML patients in molecular remission after donor lymphocyte transfusion for post-BMT relapse
We have read with interest the article of van Rhee et al 1 dealing with donor lymphocyte transfusion (DLT) for treatment of CML relapse in patients after BMT. Among other aspects the authors touch on the problem of durability of remissions after DLT treatment. They conclude that the responses to DLT are durable. On the basis of our results we cannot confirm this statement.
Since 1994, when competitive quantitative RT-PCR (Q-RT-PCR) for the BCR/ABL transcript was introduced in our institute, we have been monitoring quantitatively post-BMT patients with persistent or reappearing PCR positivity. We use competitive Q-RT-PCR, 2 a modification of the method of Lion et al 3 with natural competitors from cell lines K562 and BV173. The modified assay permits absolute quantification and was proved to be precise and reliable by comparing its results with the mathematical model of competitive PCR. Patients with CML after BMT are followed-up by qualitative RT-PCR at regular time intervals suggested by the group of European Investigators on CML (EICML group), 4 ie at 3 month intervals in the first year after BMT when two-step PCR results are negative and at 6 month intervals during further years of PCR negativity. In patients with persistent post-BMT or reappearing PCR positivity quantitative PCR analyses are performed at 1 month or shorter intervals. From our own experience, this time schedule is highly useful and in fact necessary for use in practice to enable an early detection of imminent disease relapse. On the other hand, it is enormously labour intensive. Molecular (PCR) relapse is defined as a 10 times or higher increase of PCR positivity 4 without any signs of cytogenetic relapse. Molecular remission is a stage with nondetectable positivity by two-step PCR.
Seven patients with CML relapse after allogeneic BMT were treated with DLT or the combination of DLT with interferon-␣ (IFN). One patient treated with DLT ϩ IFN in hematological relapse died, another treated with DLT alone in cytogenetic relapse showed a decrease in the number of leukemic cells but he has not achieved molecular remission up to now, 29 months after DLT. Five other patients treated with DLT or DLT ϩ IFN as early as in molecular or cytogenetic relapse achieved complete molecular remission in 1.5-5 months. However, we did not find the effect of DLT to be durable. In spite of the small number of patients we found a late molecular relapse in two patients at 20 and 29 months after DLT, ie after 18.5 and 24 months in molecular remission post DLT, respectively. The remaining three patients are in molecular remission for 3, 11 and 29 months.
Patient A (Figure 1a ), a 28-year-old man in the first chronic phase, underwent an allogeneic BMT with an unmanipulated graft from a HLA-identical sibling female donor in April 1994. The patient was splenectomized before BMT. Conditioning consisted of TBI in one fraction and cyclophosphamide. Cyclosporin A (CsA) was administered as prophylaxis against GVHD. No signs of GVHD developed after BMT. The first PCR analysis was made 4 months after BMT and showed positivity with 10 3 leukemic cells in 10 6 leukocytes. During the next 2 months the positivity increased 50-fold. A cytogenetic relapse was also detected (80% Ph positivity, 16/20). After discontinuation of CsA treatment a decrease of leukemic cells was found and after addition of IFN therapy (3 ϫ 10 6 U per day) the number of positive cells rapidly decreased below the twostep PCR detectable level. After 3.5 months the doses of IFN were lowered to 1.5 ϫ 10 6 U per day and another 2 months later the IFN treatment had to be discontinued because of side-effects. The patient remained in molecular remission with an incidental positivity on the level of twostep PCR sensitivity. However, at 24.5 months PCR positivity abruptly reached 3.3 ϫ 10 3 leukemic cells/10 6 leukocytes. This molecular relapse was treated with IFN (3 ϫ 10 6 U per day) followed with DLT (0.82 ϫ 10 8 lymphocytes per kg) after 2 weeks. The increase of leukemic cell number was stopped and already 14 days after DLT we observed a rapid decrease. A mild acute skin GVHD of grade I developed. A month later the patient was again PCR negative. During a further 17-19 months the patient remained in molecular remission with several positivities at the limit of two-step PCR sensitivity. However, 45 months after BMT, ie 20 months after DLT, the patient relapsed for the third time. In this molecular relapse the number of leukemic cells rose to 4 ϫ 10 2 leukemic cells in 10 6 leukocytes. Further increase was stopped with DLT (0.58 ϫ 10 8 lymphocytes per kg). No signs of GVHD developed. After 6 weeks of stable state the number of leukemic cells started to decrease. However, the decrease stopped and up to now, 8 months after DLT, molecular remission has not been achieved. The response to DLT treatment is less effective than in the case of the second relapse, when a higher dose of lymphocytes with combination of IFN was given.
Patient B (Figure 1b) , a 30-year-old man, was transplanted in the first chronic phase with unmanipulated graft from a HLA-identical sibling male donor in November 1992. Conditioning included fractionated TBI and cyclophosphamide. CsA was administered as prophylaxis against GVHD. As no signs of GVHD developed after BMT the treatment was interrupted after a year. The patient was found to be PCR positive at 1 year after BMT, with 3.3 ϫ 10 3 positive cells in 10 6 leukocytes. From then for more than 14 months, he was in a stable state. Then the number of positive cells gradually started to increase to 2 ϫ 10 5 leukemic cells in 10 6 leukocytes. The increase, which was also classified as a cytogenetic relapse with 18.4% Ph positivity (7/38) and two marker chromosomes, was stopped by DLT (1.63 ϫ 10 8 lymphocytes per kg) and after 3 days with IFN treatment (3 ϫ 10 6 U per day, after 2 months 3 ϫ 10 6 U given three times a week and after another 2 months the treatment was discontinued). A mild acute skin GVHD of grade I occurred. Two months later the number of positive cells started to decrease and after a further 4 months the patient entered molecular remission. During the following 22-23 months the patient remained PCR negative with several incidental positivities on the level of two-step PCR sensitivity. After 62 months post BMT (29 months after DLT) a molecular relapse appeared again with 6 ϫ 10 2 leukemic cells in 10 6 leukocytes. However, the increase stopped spontaneously and the number of leukemic cells has now been constant for 3 months.
We report here late relapses, after 18.5 and 24 months of molecular remission, in two patients after DLT treatment for post-BMT relapse. In both patients only molecular relapse was observed. In patient A the progression to cytogenetic relapse was stopped by DLT. However, it is very probable that spontaneous remission would not be achieved. A gradual increase of the BCR/ABL transcript amount found over 3 months by three sequential analyses is not a good prognostic factor. DLT was therefore applied. In patient B the increase of the BCR/ABL transcripts stopped spontaneously and at present the positivity remains constant. The dynamics of minimal residual disease in this patient are quite different from patient A. The GVL effect in patient B is probably sufficient, at least to some extent, to keep the growth of the leukemic clone under control, which is displayed by a stable level of BCR/ABL transcripts. However, the balance can be upset. Unfortunately, in the case of the first relapse it was in favor of leukemic cell proliferation. Therefore, also in this patient the molecular relapse, although spontaneously stopped, is probably a bad prognostic factor. Quantitative monitoring at short intervals is necessary to check the proliferation activity of the malignant clone.
Another problem we met was the support of the DLT effect by IFN administration. IFN is not supposed to be generally required to intensify the DLT effect. However, we found, in our small group of patients, that in almost all cases molecular remission was achieved more quickly if the relapse was treated with DLT ϩ IFN than DLT alone. In some patients, a contribution of IFN to DLT effect is probably necessary. The positive effect of IFN-␣ might be explained by the ability of IFN-␣ to upregulate the production of IFN-␥, 5 which is known to be an important inducer of the immune response. 6 Another issue is the durability of remission after DLT vs DLT ϩ IFN treatment. Both patients presented in this paper relapsed post-DLT ϩ IFN treatment. However, studies dealing with this problem are not yet available.
In conclusion, based on our results and in agreement with others, 7, 8 we do not consider the effect of DLT to be durable in all patients. In some cases, perhaps very seldom, relapses after successful DLT can occur. The GVL effect may fail as a consequence of T cell clonal exhaustion, the appearance of anergy or any other change in the complex relation between T cells and their GVL targets.
